Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019
Three years after the first identification of C. aurisin New York, pan-resistant isolates remain rare. Continued surveillance for C. auris, prudent antifungal use, and susceptibility testing for all C. aurisclinical isolates (especially after patients have been treated with antifungal drugs) are needed.
Registration now open:
International Masterclass AMR 29 SEP delivered digitally: 2 = 1!
- Science, Health-Economic & Societal impact
- Global causes and global solutions
- Bottom-up, interactive approach
- International Experts involved